Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care
Completed
- Conditions
- Acute Myeloid Leukemia
- Registration Number
- NCT00161668
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Brief Summary
This study is designed to assess the safety of Mylotarg therapy in routine practice.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
- Treated by Mylotarg
- Provide ICF
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method